Resources with keywords: vaccination
CDC has updated interenational travel recommendations for an increased number of countries to “Level 2 – Practice Enhanced Precautions”. This page will be updated reguarly based on circulating polio cases.
Poliovirus PHEIC ongoing since 2014. WHO and CDC require all laboratory workers handling poliovirus or specimens potentially containing poliovirus to be fully vaccinated with IPV. Following global certification of wild poliovirus type 2 and type 3 eradication, all WPV2 and WPV3 work must occur in poliovirus-essential facilities (PEFs) under WHO Global Action Plan III (GAPIII) containment standards. USDA ARS laboratories should confirm no unauthorized poliovirus materials are retained in freezer inventories.
The CDC said 976 of the US cases were in 26 states, while six are related to international travel. The agency also confirmed seven new outbreaks in 2026, compared with 49 that began in 2025.
ACIP’s recommendation applies to all individuals six months and older. It includes an emphasis that the risk-benefit of vaccination in individuals under age 65 is most favorable for those who are at an increased risk for severe COVID-19 and lowest for individuals who are not at an increased risk, according to the CDC list of COVID-19 risk factors.
Recommendations made by the ACIP are reviewed by the CDC Director, and if adopted, are published as official CDC/HHS recommendations in the Morbidity and Mortality Weekly Report.
Includes information on who should be vaccinated, how to find vaccines, free vaccines, etc.
Good background information and outbreak updates on Measles outbreak in Texas and NM.
Includes recommendations for clinicians, public health departments and travellers.
P Bager, et al.
An observational study comparing the severity of COVID-19 and influenza among nearly 6 million Denmark residents finds a higher rate of hospitalizations and deaths in those infected with SARS-CoV-2—mainly among unvaccinated people, those with chronic conditions, and males—from 2022 to 2024.
CDC endorsing that people 65 years and older and those who are moderately or severely immunocompromised receive a second dose of 2024-2025 COVID-19 vaccine six months after their first dose.
